試す - 無料

Bio Spectrum - December 2022

filled-star
Bio Spectrum

Magzter GOLDで無制限に

読む Bio Spectrum 9,500以上の雑誌や新聞を1回の定期購読で購読できます  

カタログを見る

1ヶ月

$14.99

1年

$149.99

$12/month

(OR)

Bio Spectrumのみを購読する

この号を購入: December 2022

December 2022 から始まる 1 号

December 2022 から始まる 12 号

この号を購入する

$0.99

1年

$10.99

Please choose your subscription plan

いつでもキャンセルできます。

(義務なし) ⓘ

定期購読にご満足いただけない場合は、定期購読開始日から 7 日以内に help@magzter.com までメールをお送りいただければ、全額返金いたします。質問は一切ありません。お約束します! (注: 単号購入には適用されません)

デジタルサブスクリプション

即時アクセス ⓘ

今すぐ購読すると、Magzter の Web サイト、iOS、Android、Amazon アプリですぐに読み始めることができます。

安全性を確認済み

支払い ⓘ

Magzter は Authorize.Net の認定販売業者です。詳細はこちら

この号では

Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed a steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency’ in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.

Bio Spectrum Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

最近の問題

  • March 2013

    March 2013

関連タイトル

人気カテゴリー